|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 328.16 USD | -0.93% |
|
-2.93% | -17.48% |
| 01-27 | Intellia gets FDA nod to resume one gene therapy trial after safety pause | RE |
| 01-20 | RBC Cuts Price Target on Alnylam Pharmaceuticals to $465 From $500, Keeps Outperform Rating | MT |
Company Valuation: Alnylam Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15,100 | 20,282 | 29,238 | 24,021 | 30,350 | 43,354 | 43,354 | - |
| Change | - | 34.32% | 44.16% | -17.84% | 26.35% | 42.85% | 0% | - |
| Enterprise Value (EV) 1 | 13,417 | 18,522 | 28,132 | 23,979 | 30,128 | 41,728 | 40,315 | 38,244 |
| Change | - | 38.05% | 51.88% | -14.76% | 25.64% | 38.5% | -3.39% | -5.14% |
| P/E ratio | -17.4x | -23.6x | -25.6x | -54.4x | -108x | 139x | 47.8x | 28.1x |
| PBR | 14.9x | 34.6x | -186x | -109x | 453x | 49.6x | 15.8x | 8.5x |
| PEG | - | 6.77x | -0.9x | 0.9x | 2.8x | -1x | 0x | 0.4x |
| Capitalization / Revenue | 30.6x | 24x | 28.2x | 13.1x | 13.5x | 11.5x | 7.82x | 6.09x |
| EV / Revenue | 27.2x | 21.9x | 27.1x | 13.1x | 13.4x | 11.1x | 7.27x | 5.37x |
| EV / EBITDA | -16.9x | -28x | -38x | -105x | -251x | 76.8x | 33.1x | 20.2x |
| EV / EBIT | -16.2x | -26.1x | -35.8x | -85x | -170x | 72x | 35x | 19.7x |
| EV / FCF | -19.6x | -25.8x | -45.9x | 572x | -707x | 74.5x | 28.4x | 17.7x |
| FCF Yield | -5.11% | -3.88% | -2.18% | 0.17% | -0.14% | 1.34% | 3.52% | 5.63% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.46 | -7.2 | -9.3 | -3.52 | -2.18 | 2.362 | 6.861 | 11.69 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 492.9 | 844.3 | 1,037 | 1,828 | 2,248 | 3,774 | 5,546 | 7,118 |
| EBITDA 1 | -793.7 | -661.1 | -740.6 | -228.1 | -120.2 | 543.4 | 1,219 | 1,895 |
| EBIT 1 | -828.4 | -708.7 | -785.1 | -282.2 | -176.9 | 579.7 | 1,150 | 1,939 |
| Net income 1 | -858.3 | -852.8 | -1,131 | -440.2 | -278.2 | 316.3 | 933.4 | 1,607 |
| Net Debt 1 | -1,683 | -1,760 | -1,105 | -41.37 | -222.5 | -1,626 | -3,039 | -5,111 |
| Reference price 2 | 129.97 | 169.58 | 237.65 | 191.41 | 235.31 | 328.16 | 328.16 | 328.16 |
| Nbr of stocks (in thousands) | 116,181 | 119,601 | 123,028 | 125,493 | 128,981 | 132,114 | 132,114 | - |
| Announcement Date | 11/02/21 | 10/02/22 | 23/02/23 | 15/02/24 | 13/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 138.94x | 11.06x | 76.79x | -.--% | 43.35B | |
| 46.93x | 15.27x | 33.84x | 0.55% | 947B | |
| 21.8x | 6.43x | 17.86x | 2.15% | 578B | |
| 62.39x | 7.4x | 18.34x | 2.93% | 395B | |
| 18.44x | 4.63x | 11.48x | 2.82% | 367B | |
| 15.75x | 5.05x | 11.01x | 2.65% | 303B | |
| 30.26x | 5.44x | 16.24x | 1.69% | 298B | |
| 20.34x | 5.75x | 14.03x | 2.98% | 295B | |
| 13.96x | 4.82x | 10.24x | 3.65% | 208B | |
| 29.86x | 6.92x | 11.85x | 2.49% | 207B | |
| Average | 39.87x | 7.28x | 22.17x | 2.19% | 364.06B | |
| Weighted average by Cap. | 33.88x | 8.39x | 20.34x | 2.04% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ALNY Stock
- Valuation Alnylam Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition